

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Fruquintinib (Fruzaqla)

Notes:

- Quantity Limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **Fruquintinib (Fruzaqla)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of metastatic colorectal cancer
- Prescribed by Oncology/Hematology provider
- Patient has failed an adequate trial[^] of intravenous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, and trifluridine-tipiracil, or have contraindications or intolerance to these agents.

Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **Fruquintinib (Fruzaqla)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of metastatic colorectal cancer
- Prescribed by Oncology/Hematology provider
- Patient has failed an adequate trial[^] of intravenous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, and trifluridine-tipiracil, or have contraindications or intolerance to these agents.

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary **Fruquintinib (Fruzaqla)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of metastatic colorectal cancer
- Prescribed by Oncology/Hematology provider
- Patient has failed an adequate trial[^] of intravenous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, and trifluridine-tipiracil, or have contraindications or intolerance to these agents.